Cusi K - Search Results

1

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Among authors: cusi k. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. Hepatology. 2023. PMID: 37363821 Free PMC article.

2

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.

Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. Kashyap S, et al. Among authors: cusi k. Diabetes. 2003 Oct;52(10):2461-74. doi: 10.2337/diabetes.52.10.2461. Diabetes. 2003. PMID: 14514628 Clinical Trial.

3

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.

Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E. Cusi K, et al. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1775-81. doi: 10.1152/ajpendo.00624.2006. Epub 2007 Feb 13. Am J Physiol Endocrinol Metab. 2007. PMID: 17299078 Free article. Clinical Trial.

4

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.

Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K. Balas B, et al. Among authors: cusi k. J Hepatol. 2007 Oct;47(4):565-70. doi: 10.1016/j.jhep.2007.04.013. Epub 2007 May 24. J Hepatol. 2007. PMID: 17560678 Clinical Trial.

5

Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.

Kashyap SR, Belfort R, Cersosimo E, Lee S, Cusi K. Kashyap SR, et al. Among authors: cusi k. J Cardiometab Syndr. 2008 Summer;3(3):141-6. doi: 10.1111/j.1559-4572.2008.00013.x. J Cardiometab Syndr. 2008. PMID: 18983329

6

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Gastaldelli A, et al. Among authors: cusi k. Hepatology. 2009 Oct;50(4):1087-93. doi: 10.1002/hep.23116. Hepatology. 2009. PMID: 19670459 Clinical Trial.

7

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

Belfort R, Berria R, Cornell J, Cusi K. Belfort R, et al. Among authors: cusi k. J Clin Endocrinol Metab. 2010 Feb;95(2):829-36. doi: 10.1210/jc.2009-1487. Epub 2010 Jan 8. J Clin Endocrinol Metab. 2010. PMID: 20061429 Free PMC article. Clinical Trial.

8

Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.

Glass LC, Cusi K, Berria R, Petz R, Cersosimo E, Defronzo RA, Gastaldelli A. Glass LC, et al. Among authors: cusi k. Clin Endocrinol (Oxf). 2010 Sep;73(3):339-45. doi: 10.1111/j.1365-2265.2010.03811.x. Epub 2010 Apr 23. Clin Endocrinol (Oxf). 2010. PMID: 20455891 Free PMC article. Clinical Trial.

9

Pioglitazone in the treatment of NASH: the role of adiponectin.

Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K. Gastaldelli A, et al. Among authors: cusi k. Aliment Pharmacol Ther. 2010 Sep;32(6):769-75. doi: 10.1111/j.1365-2036.2010.04405.x. Aliment Pharmacol Ther. 2010. PMID: 20662773 Free article. Clinical Trial.

10

Insulin sensitizers in nonalcoholic steatohepatitis.

Harrison SA, Schenker S, Cusi K. Harrison SA, et al. Among authors: cusi k. Hepatology. 2011 Apr;53(4):1404-5; author reply 1405. doi: 10.1002/hep.24179. Hepatology. 2011. PMID: 21480350 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page